Vistagen Completes Phase 3 Trial for Fasedienol in Social Anxiety Disorder; Topline Results Expected Q2 2026
VTGN sits 42% above its 52-week low of $0.43.
Summary
Vistagen Therapeutics announced the completion of the randomized portion of its PALISADE-4 Phase 3 clinical trial for fasedienol, with topline results anticipated in the second quarter of 2026.
Key Events · Product Development and Regulatory · VTGN
-
Phase 3 Trial Completion
The last patient has completed their last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Phase 3 clinical trial evaluating fasedienol nasal spray for social anxiety disorder.
-
Topline Results Expected
Topline results from the randomized portion of the PALISADE-4 study are expected in the second quarter of 2026.
-
Statistical Analysis Plan Refined
Vistagen refined the statistical analysis plan (SAP) for PALISADE-4 to incorporate baseline distress levels, and the FDA has informed the company it has no comments on these refinements.
Analysis · VTGN · Life Sciences
Vistagen Therapeutics has reached a critical milestone by completing the randomized portion of its PALISADE-4 Phase 3 clinical trial for fasedienol, a lead candidate for social anxiety disorder. This development is highly important, especially given the company's previously disclosed 'going concern' warning and Nasdaq delisting threat. The successful completion of this trial phase, coupled with the FDA's non-objection to the refined statistical analysis plan, de-risks the operational aspect of the study and sets the stage for the highly anticipated topline results in Q2 2026. These results will be a major catalyst for the company, potentially addressing its financial viability and future prospects.
At the time of this filing, VTGN was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $0.43 to $5.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.